What is Roth Capital’s Estimate for Cresco Labs Q1 Earnings?

Cresco Labs Inc. (OTCMKTS:CRLBF) – Research analysts at Roth Capital issued their Q1 2025 EPS estimates for shares of Cresco Labs in a report released on Thursday, March 13th. Roth Capital analyst W. Kirk expects that the company will post earnings of ($0.03) per share for the quarter. The consensus estimate for Cresco Labs’ current full-year earnings is ($0.20) per share. Roth Capital also issued estimates for Cresco Labs’ Q2 2025 earnings at ($0.02) EPS, Q3 2025 earnings at ($0.02) EPS, Q4 2025 earnings at ($0.01) EPS, FY2025 earnings at ($0.08) EPS and FY2026 earnings at ($0.04) EPS.

Cresco Labs (OTCMKTS:CRLBF) last issued its quarterly earnings results on Friday, March 14th. The company reported ($0.01) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.01). The company had revenue of $176.00 million for the quarter, compared to the consensus estimate of $172.10 million. Cresco Labs had a negative net margin of 9.15% and a negative return on equity of 16.52%.

Separately, Atb Cap Markets cut Cresco Labs from a “strong-buy” rating to a “hold” rating in a research note on Monday, December 9th. Three equities research analysts have rated the stock with a hold rating, one has issued a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $3.00.

Cresco Labs Price Performance

Shares of OTCMKTS:CRLBF opened at $0.75 on Monday. The company’s 50-day moving average is $0.89 and its 200 day moving average is $1.20. The company has a debt-to-equity ratio of 1.80, a quick ratio of 1.39 and a current ratio of 1.97. The company has a market capitalization of $364.25 million, a P/E ratio of -3.73 and a beta of 1.79. Cresco Labs has a fifty-two week low of $0.70 and a fifty-two week high of $2.60.

Cresco Labs Company Profile

Cresco Labs Inc, together with its subsidiaries, cultivates, manufactures, and sells retail and medical cannabis products in the United States. It provides cannabis in flowers, vape pens, live resins, disposable pens, and extracts under the Cresco brand; vape carts, vape pens, flower, popcorn, shake, pre-rolls, shorties, and concentrates under the High Supply brand; vapes and gummies under the Good News brand; vapes and edibles under the Wonder Wellness Co brand; and tinctures, capsules, salves, and sublingual oils under the Remedi brand.